Company Overview
Ipca Laboratories Limited reported strong financial performance for FY 2025-26 with significant growth across key metrics. The company achieved standalone revenue of ₹7,431.39 Crores, representing a 10.11% increase from the previous year, while net profit surged 74.03% to ₹1,132.52 Crores.
Financial Performance Highlights
Income Statement: Total income reached ₹7,431.39 Crores (FY 2025-26) versus ₹6,749.21 Crores (FY 2024-25), with domestic income at ₹4,301.96 Crores (9% growth) and export income at ₹3,129.43 Crores (11% growth). Profit Before Tax stood at ₹1,532.13 Crores (53.25% growth) while Net Profit After Tax reached ₹1,132.52 Crores.
Balance Sheet & Ratios: Net Worth increased to ₹7,979.35 Crores from ₹6,891.62 Crores. Key financial ratios showed improvement with Operating Profit Margin at 21.51% (vs 18.89%), Net Profit Margin at 15.24% (vs 9.64%), and Return on Net Worth at 14.19% (vs 9.44%). Debt Equity Ratio improved to 0.03 from 0.13.
Segment Performance: Formulations Business contributed ₹5,899.82 Crores (10% growth) while APIs & Intermediates generated ₹1,395.74 Crores (10% growth).
Corporate Actions & Dividend
The Board recommended a dividend of ₹6 per equity share (600%) totaling ₹152.22 Crores, with record date set for August 7, 2026. The company proposed reappointment of Executive Director Prashant Godha for five years from August 16, 2026, along with reappointment of Managing Directors Ajit Kumar Jain and Pranay Godha.
Manufacturing Expansion & Divestment
Ipca commissioned a new greenfield Drug Intermediates/APIs facility in Wardha, Maharashtra (₹182 Crores capital outlay) and is developing new formulations units in Dewas, Madhya Pradesh (₹275 Crores) and monoclonal antibodies facility in Pithampur (₹250 Crores). The company divested two non-core manufacturing units at Tarapur, Maharashtra and Ankleshwar, Gujarat on slump sale basis.
Subsidiary Investments & Regulatory Matters
Investments in subsidiaries increased to ₹2,161.88 crores with additional funding to Ipca Pharmaceuticals Inc. USA for Pisgah Laboratories expansion. The Group settled a European Commission fine of €19.55 million (₹203.89 crores) in full during the year, recording an exceptional interest charge of ₹58.26 crores. The company also recognized ₹45.82 crores as exceptional item for incremental liability from new labour codes.
Capital Expenditure & Investments
Capital Work-in-Progress stood at ₹761.59 crores, primarily for manufacturing facilities at Pithampur (Phase II) expected to capitalize next year. Investments in joint ventures and associates totaled ₹183.61 crores, with full provision of ₹118.90 crores made for exposure in preference capital of associate Krebs Biochemicals.
Corporate Governance & Compliance
The 76th Annual General Meeting is scheduled for August 13, 2026 via VC/OAVM. The company maintained strong credit ratings from India Ratings & Research: Commercial Paper at IND A1+ and Working Capital Limits at IND AA+/Stable/IND A1+. Total permanent employees stood at 18,667 with women employees representing 6.96% of workforce.
Research & Development
R&D expenditure increased to ₹246.09 Crores (3.37% of turnover) from ₹207.08 Crores. The company filed 46 ANDAs with US FDA (32 approved), 50 DMFs with US FDA, and submitted 65 generic formulation dossiers in Europe (60 registered).